

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

FLT3 (8F2) Rabbit mAb

RRID:AB_2107052

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3462, RRID:AB_2107052

Antibody Information

URL: http://antibodyregistry.org/AB_2107052

Proper Citation: Cell Signaling Technology Cat# 3462, RRID:AB_2107052

Target Antigen: FLT3 (8F2) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10693420, AB_2107052.

Antibody Name: FLT3 (8F2) Rabbit mAb

Description: This monoclonal targets FLT3 (8F2) Rabbit mAb

Target Organism: h, m, mouse, human

Antibody ID: AB_2107052

Vendor: Cell Signaling Technology

Catalog Number: 3462

Record Creation Time: 20250819T212338+0000

Record Last Update: 20250819T224829+0000

Ratings and Alerts

No rating or validation information has been found for FLT3 (8F2) Rabbit mAb.

No alerts have been found for FLT3 (8F2) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang D, et al. (2025) FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia. *Cell reports. Medicine*, 102365.

Wang P, et al. (2024) Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib. *Cancer research*, 84(6), 905.

Momenilandi M, et al. (2024) FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. *Cell*, 187(11), 2817.

Chen M, et al. (2024) Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling. *Cell reports. Medicine*, 5(7), 101645.

Sabatier M, et al. (2023) C/EBP β Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia. *Cancer discovery*, 13(7), 1720.

Long J, et al. (2023) A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment. *Cell reports. Medicine*, 4(11), 101286.

Wang E, et al. (2023) Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. *Cancer cell*, 41(1), 164.

Ghezzi C, et al. (2023) Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3. *Scientific reports*, 13(1), 1442.

Synn CB, et al. (2022) SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models. *Clinical & translational immunology*, 11(1), e1364.

Joshi SK, et al. (2021) The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. *Cancer cell*, 39(7), 999.

Bhatt S, et al. (2020) Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. *Cancer cell*, 38(6), 872.